Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Latuda Lurasidone Schizophrenia Do not list Complete
Latuda Lurasidone Schizophrenia List with criteria/condition Complete
Lazcluze and Rybrevant lazertinib and amivantamab Locally advanced or metastatic non-small cell lung cancer (NSCLC) Received
Ledaga chlormethine hydrochloride T-cell lymphoma Do not reimburse Complete
Lemtrada Alemtuzumab Multiple sclerosis, relapsing-remitting Withdrawn
Lemtrada Alemtuzumab Multiple sclerosis, relapsing-remitting List with criteria/condition Complete
Lenvima Lenvatinib Renal Cell Carcinoma (RCC) Do not reimburse Complete
Lenvima Lenvatinib Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Complete
Lenvima Lenvatinib Differentiated Thyroid Cancer Reimburse with clinical criteria and/or conditions Complete
Lenvima and Keytruda lenvatinib and pembrolizumab advanced or metastatic renal cell carcinoma Reimburse with clinical criteria and/or conditions Complete